Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers

Purpose: This study is an expanded and parallel clinical trial of EGFR-specific chimeric antigen receptor–engineered autologous T (CART) cell immunotherapy (NCT01869166) to assess the safety and activity of CART-EGFR cell therapy in EGFR-positive advanced unresectable, relapsed/metastatic biliary tract cancers (BTC). Experimental Design: Patients with EGFR-positive (>50%) advanced unresectable, relapsed/metastatic BTCs were enrolled. Well-produced CART-EGFR cells were infused in a manner of dose escalation after the conditioning treatment with nab-paclitaxel (100–250 mg/m2) and cyclophosphamide (15–35 mg/kg). Results: A total of 19 patients (14 cholangiocarcinomas and 5 gallbladder carcinomas) received one to three cycles of CART-EGFR cell infusion (median CART cell dose, 2.65 × 106/kg; range, 0.8–4.1 × 106/kg) within 6 months. The CART-EGFR cell infusion was tolerated, but 3 patients suffered grade ≥3 acute fever/chill. Grade 1/2 target-mediated toxicities including mucosal/cutaneous toxicities and acute pulmonary edema and grade ≥3 lymphopenia and thrombocytopenia related to the conditioning treatment were observed. Of 17 evaluable patients, 1 achieved complete response and 10 achieved stable disease. The median progression-free survival was 4 months (range, 2.5–22 months) from the first cycle of treatment. Analysis of data indicated that the enrichment of central memory T cells (Tcm) in the infused CART-EGFR cells improved the clinical outcome. Conclusions: The CART-EGFR cell immunotherapy was a safe and active strategy for EGFR-positive advanced BTCs. The enrichment of Tcm in the infused CART-EGFR cells could predict clinical response. Clin Cancer Res; 24(6); 1277–86. ©2017 AACR. See related commentary by Kalos, p. 1246

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-11-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-0432PMID 29138340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New development in CAR-T cell therapy

  2017cited by this paper
• PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

  2017cited by this paper
• Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

  2017cited by this paper
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

  2016cited by this paper
• A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

  2016cited by this paper
• Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects

  2016cited by this paper
• Prospects for gene-engineered T cell immunotherapy for solid cancers

  2016cited by this paper
• Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

  2016cited by this paper
• Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

  2016cited by this paper
• The epigenetic landscape of T cell exhaustion

  2016cited by this paper
• PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

  2016cited by this paper
• Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

  2016cited by this paper
• SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts

  2016cited by this paper
• Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas

  2015cited by this paper
• Immunological hallmarks of stromal cells in the tumour microenvironment

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

  2015cited by this paper
• Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

  2015cited by this paper
• HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity

  2015cited by this paper
• Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application

  2015cited by this paper
• A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

  2015cited by this paper
• Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

  2015cited by this paper
• Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.

  2015cited by this paper
• Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases

  2015cited by this paper
• Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.

  2014cited by this paper
• Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.

  2014cited by this paper
• Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer

  2014cited by this paper
• Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

  2014cited by this paper
• Current concepts in the diagnosis and management of cytokine release syndrome.

  2014cited by this paper
• Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

  2014cited by this paper
• Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.

  2014cited by this paper
• Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.

  2013cited by this paper
• TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

  2013cited by this paper
• PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

  2013cited by this paper
• Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

  2012cited by this paper
• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

  2012cited by this paper
• A human memory T-cell subset with stem cell-like properties

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

  2011cited by this paper
• Cholangiocarcinoma: Epidemiology, Risk Factors, Pathogenesis, and Diagnosis

  2011cited by this paper
• Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

  2010cited by this paper
• Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

  2010cited by this paper
• Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

  2010cited by this paper
• Mechanisms of resistance to HER family targeting antibodies.

  2010cited by this paper
• Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

  2009cited by this paper
• Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

  2007cited by this paper
• Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

  2006influential reference
• A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

  2006cited by this paper
• Phase II study of erlotinib in patients with advanced biliary cancer.

  2006cited by this paper
• Mini Review Article

  year unknowncited by this paper

• Nanoparticles-mediated SLAMF7 overexpression regulates TME for enhanced immunotherapy of solid tumors

  2026cites this paper
• Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer

  2026cites this paper
• A framework integrating multiscale in silico modeling and experimental data predicts CAR-NK cell cytotoxicity across target cell types

  2026cites this paper
• Programming T cells for Early Cancer Detection with Customized Protease-Activatable Receptors

  2026cites this paper
• Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions.

  2026cites this paper
• Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours.

  2026cites this paper
• Glutamate metabotropic receptor 4 in breast cancer: a potential and specific target for chimeric antigen receptor therapy

  2026cites this paper
• The activity of EGFR CAR-NK and CAR-T cells against EGFR inhibitor-resistant NSCLC and drug-tolerant persister cells.

  2025cites this paper
• Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond

  2025cites this paper
• Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity.

  2025cites this paper
• A framework integrating multiscale in-silico modeling and experimental data predicts CD33CAR-NK cytotoxicity across target cell types

  2025cites this paper
• In-depth analysis of the safety of CAR-T cell therapy for solid tumors

  2025cites this paper
• Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell

  2025cites this paper
• Engineering sonogenetic EchoBack-CAR T cells.

  2025cites this paper
• Immune microenvironment of tumor-draining lymph nodes: insights for immunotherapy

  2025cites this paper
• Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges

  2025cites this paper
• Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions.

  2025cites this paper
• A general logic-gating framework for CAR-T and nanocarrier cancer therapies.

  2025cites this paper
• Evolving Precision: Updates in Targeted Therapy for Cholangiocarcinoma.

  2025cites this paper
• Omics-driven networks herald a new era of multidimensional therapy for cholangiocarcinoma

  2025cites this paper
• Challenges in the preclinical design and assessment of CAR-T cells

  2025cites this paper
• Complications of Chimeric Antigen Receptor T-cell Therapy.

  2025cites this paper
• Oncogene Mutations: The Shared Antigen Vaccines That Work?

  2025cites this paper
• Innovative approaches to CAR-T cell therapy: the role of lipid metabolism pathways

  2025cites this paper
• Targeted therapies and immunotherapies for unresectable cholangiocarcinoma

  2025cites this paper
• Emerging therapeutic approaches for cholangiocarcinoma: harnessing natural compounds and targeted therapies with proposed cellular mechanism

  2025cites this paper
• What is the Best Option for Cellular Immunotherapies in Triple-Negative Breast Cancer? A Systematic Review Based on in vitro and in vivo Evidences

  2025cites this paper
• Immune Landscape of Intrahepatic Cholangiocarcinoma: Evasion and Therapeutic Insights

  2025cites this paper
• CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors—A narrative review

  2025cites this paper
• Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients

  2025cites this paper
• Recent advancements in systemic therapy for biliary tract cancers: a literature review

  2025cites this paper
• Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors

  2025cites this paper
• Frontiers in mechanobiology and mechanomedicine

  2025cites this paper
• Precision medicine for advanced biliary tract cancer in China: current status and future perspectives

  2025cites this paper
• New targets and new drugs for hepatobiliary cancers.

  2025cites this paper
• A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells

  2025cites this paper
• Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.

  2025cites this paper
• Digestive cancers: mechanisms, therapeutics and management

  2025cites this paper
• The next generation of immunotherapies for lung cancers

  2025cites this paper
• Optimizing CAR T cell therapy for solid tumours: a clinical perspective

  2025cites this paper
• CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges

  2025cites this paper
• Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications

  2025cites this paper
• CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells

  2025cites this paper
• Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers

  2025cites this paper
• Current status and perspectives of clinical trials for tumor-infiltrating lymphocyte therapy

  2024cites this paper
• New systemic treatment options for advanced cholangiocarcinoma

  2024cites this paper
• The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma

  2024cites this paper
• Left out in the cold: moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.

  2024cites this paper
• Methodological Approaches for Increasing the Retroviral Transduction Efficiency of Primary NK Cells.

  2024cites this paper
• Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.

  2024cites this paper
• Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development.

  2024cites this paper
• Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma

  2024cites this paper
• Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.

  2024cites this paper
• FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy

  2024cites this paper
• Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions

  2024cites this paper
• CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2024cites this paper
• CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

  2024cites this paper
• CAR-T cell therapy in advanced thyroid cancer: from basic to clinical

  2024cites this paper
• Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity

  2024cites this paper
• Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control

  2024cites this paper
• Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives

  2024cites this paper
• Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer

  2024influential citation
• Tumor-associated antigen targets for novel immune-based strategies in prostate cancer

  2024cites this paper
• An Unusual Case of Low Vision and Anisocoria Considered a Neurological Finding in the Emergency Department: Ocular Siderosis

  2024cites this paper
• Immunotherapy and Targeted Therapy for Cholangiocarcinoma: Artificial Intelligence Research in Imaging.

  2024cites this paper
• CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad

  2024cites this paper
• Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells

  2024cites this paper
• Immunotherapy for the treatment of biliary tract cancer: an evolving landscape

  2024influential citation
• Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges.

  2024cites this paper
• Exploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma

  2024cites this paper
• Lymphodepletion in Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: A Focus on Brain Tumors

  2024cites this paper
• Enhancing CAR-T cell therapy against solid tumor by drug-free triboelectric immunotherapy.

  2024cites this paper
• Peripheral blood-derived PD-1/CD28-CD19-CAR-modified PD-1+ T-cell therapy in patients with solid tumors.

  2024cites this paper
• Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy

  2024cites this paper
• CAR T-cells for pediatric solid tumors: where to go from here?

  2024cites this paper
• Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer.

  2024cites this paper
• MicroRNAs and RNA-Binding Protein-Based Regulation of Bone Metastasis from Hepatobiliary Cancers and Potential Therapeutic Strategies

  2024cites this paper
• Intra- and Extrahepatic Cholangiocarcinomas Display Differing Sensitivities to NK Cell Lysis and Modulate NK Cell Function Through Shared and Distinct Pathways.

  2024cites this paper
• Adoptive T cell therapy for solid tumors: current landscape and future challenges

  2024cites this paper
• Ex vivo T cell differentiation in adoptive immunotherapy manufacturing: Critical process parameters and analytical technologies.

  2024cites this paper
• Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies.

  2024cites this paper
• Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials.

  2024cites this paper
• Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy

  2024cites this paper
• Inconsistent reporting and definitions of time-to-event endpoints in CAR T clinical trials: A review.

  2024cites this paper
• Cholangiocarcinoma in the Era of Immunotherapy

  2023cites this paper
• Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors.

  2023cites this paper
• Update on immunotherapy in the management of gallbladder cancer.

  2023cites this paper
• Time to abandon CAR-T monotherapy for solid tumors.

  2023cites this paper
• An Overview of the Therapeutic Development of Cholangiocarcinoma with Special Emphasis on Targeted and Biologic Therapies

  2023cites this paper
• Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report

  2023cites this paper
• Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers

  2023cites this paper
• Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins

  2023cites this paper
• A Multiscale Protein Abundance Structured Population Kinetic Model Systematically Explores the Design Space of Constitutive and Inducible CAR-T cells

  2023cites this paper
• Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies

  2023cites this paper
• Metabolic challenges and interventions in CAR T cell therapy

  2023cites this paper
• The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

  2023cites this paper
• Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

  2023cites this paper
• Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.

  2023cites this paper
• Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.

  2023cites this paper
• Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza

  2023cites this paper